GABAB Receptor Antibodies

Metabotropic GABA receptors, collectively known as GABAB receptors, are class C GPCRs that mediate the slow and sustained inhibitory actions of the neurotransmitter γ-aminobutyric acid (GABA) in the central and peripheral nervous systems. The functional receptor is an obligate heterodimer composed of GABAB1 and GABAB2 subunits, with GABAB1 responsible primarily for ligand recognition and GABAB2 for efficient G-protein coupling and signaling. GABAB receptors are predominantly coupled to Gi/o proteins, resulting in inhibition of adenylyl cyclase, reduced cAMP production, activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels. These mechanisms reduce neuronal excitability and suppress the release of neurotransmitters such as glutamate, GABA, dopamine and noradrenaline. GABAB receptors are widely expressed throughout the brain and spinal cord, including the cerebral cortex, hippocampus, thalamus, cerebellum, basal ganglia and spinal dorsal horn. They are located both postsynaptically, where they produce neuronal hyperpolarization, and presynaptically, where they function as autoreceptors or heteroreceptors controlling neurotransmitter release. GABAB signaling is therefore involved in synaptic inhibition, neuronal network activity, muscle tone, pain processing, seizure control, anxiety and addiction-related behaviors. Pharmacological activation of GABAB receptors can produce strong muscle-relaxant, antispastic, analgesic, sedative and anticonvulsant effects. Baclofen is the best-established selective GABAB receptor agonist and is an approved drug widely used to treat spasticity, particularly in multiple sclerosis and spinal cord disorders. Other GABAB agonists such as phenibut and sodium oxybate can produce GABAB-mediated effects, although their pharmacology is less selective and they have additional pharmacological actions. Several positive allosteric modulators, including CGP7930, GS39783 and newer compounds, have been developed to enhance endogenous GABA signaling without directly activating the receptor. GABAB receptor antagonists such as CGP55845 and CGP62349 are mainly experimental research tools and have not been developed into established therapies. Overall, GABAB receptors represent a well-validated inhibitory GPCR system with an established clinical drug, but the development of subtype- or pathway-selective modulators remains an attractive opportunity for treating neurological and psychiatric disorders.